Primary Pulmonary Late Side Effects Monitored
Lurbinectedin (Zepzelca), used for metastatic small cell lung cancer, requires monitoring for late-onset interstitial lung disease (ILD)/pneumonitis, which can emerge weeks to months after treatment. This includes non-infectious pneumonitis, reported in up to 10% of patients in clinical trials, with some cases progressing to severe respiratory failure or death.[1][2]
How ILD Presents and Why It's Monitored Late
ILD symptoms—dyspnea, cough, fatigue, fever, or hypoxia—may not appear during infusion but develop later, prompting ongoing surveillance via chest imaging (CT scans) and pulmonary function tests for at least 3-6 months post-treatment or longer if risk factors like prior radiation or smoking exist. Discontinuation is standard if confirmed.[1][3]
Risk Factors Increasing Late Pulmonary Concerns
Patients with pre-existing lung conditions, concurrent immunotherapy, or thoracic radiation face higher ILD risk (Grade 3-5 in 2-4% of cases). Monitoring intensifies in these groups, with baseline PFTs and serial oxygen saturation checks.[2][4]
Comparison to Other Chemotherapy Pulmonary Risks
Unlike bleomycin's early fibrosis, lurbinectedin's ILD is immune-mediated and delayed, resembling immunotherapy toxicities. No routine bronchoscopy is mandated unless diagnostic uncertainty arises.[1][5]
Guidelines for Patient Monitoring Timeline